|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Custem E, Moiseyenko VM, Tjulandin S,
et al V325 Study Group: Phase III study of docetaxel and cisplatin
plus fluorouracil compared with cisplatin and fluorouracil as
first-line therapy for advanced gastric cancer: a report of the
V325 Study Group. J Clin Oncol. 24:4991–4997. 2006. View Article : Google Scholar
|
|
3
|
Cunningham D, Starling N, Rao S, et al
Upper Gastrointestinal Clinical Studies Group of the National
Cancer Research Institute of the United Kingdom: Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med.
358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koizumi W, Narahara H, Hara T, et al: S-1
plus cisplatin versus S-1 alone for first-line treatment of
advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet
Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kang YK, Kang WK, Shin DB, et al:
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as
first-line therapy in patients with advanced gastric cancer: a
randomised phase III noninferiority trial. Ann Oncol. 20:666–673.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ajani JA, Rodriguez W, Bodoky G, et al:
Multicenter phase III comparison of cisplatin/S-1 with
cisplatin/infusional fluorouracil in advanced gastric or
gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin
Oncol. 28:1547–1553. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bang YJ, Van Custem E, Feyereislova A, et
al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohtsu A, Shah MA, Van Custem E, et al:
Bevacizumab in combination with chemotherapy as first-line therapy
in advanced gastric cancer: a randomized, double-blind,
placebo-controlled phase III study. J Clin Oncol. 29:3968–3976.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gómez-Martin C, Garralda E, Echarri MJ, et
al: HER2/neu testing for anti-HER2-based therapies in patients with
unresectable and/or metastatic gastric cancer. J Clin Pathol.
65:751–757. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Van Custem E, Köhne CH, Hitre E, et al:
Cetuximab and chemotherapy as initial treatment for metastatic
colorectal cancer. N Engl J Med. 360:1408–1417. 2009. View Article : Google Scholar
|
|
11
|
Specenier P and Vermorken JB: Cetuximab in
the treatment of squamous cell carcinoma of the head and neck.
Expert Rev Anticancer Ther. 11:511–524. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pirker R, Pereira JR, Szczesna A, et al
FLEX Study Team: Cetuximab plus chemotherapy in patients with
advanced non-small-cell lung cancer (FLEX): an open-label
randomised phase III trial. Lancet. 373:1525–1531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pinto C, Di Fabio F, Barone C, et al:
Phase II study of cetuximab in combination with cisplatin and
docetaxel in patients with untreated advanced gastric or
gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J
Cancer. 101:1261–1268. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee KH, Lee JS, Suh C, et al:
Clinicopathologic significance of the K-ras gene codon 12 point
mutation in stomach cancer. An analysis of 140 cases. Cancer.
75:2794–2801. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Davies H, Bignell GR, Cox C, et al:
Mutations of the BRAF gene in human cancer. Nature. 417:949–954.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moehler M, Mueller A, Trarbach T, et al
German Arbeitsgemeinschaft Internistische Onkologie: Cetuximab with
irinotecan, folinic acid and 5-fluorouracil as first-line treatment
in advanced gastroesophageal cancer: a prospective multi-center
biomarker-oriented phase II study. Ann Oncol. 22:1358–1366. 2011.
View Article : Google Scholar
|
|
17
|
Lordick F, Luber B, Lorenzen S, et al:
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line
metastatic gastric cancer: a phase II study of the
Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer.
102:500–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pinto C, Di Fabio F, Siena S, et al: Phase
II study of cetuximab in combination with FOLFIRI in patients with
untreated advanced gastric or gastroesophageal junction
adenocarcinoma (FOLCETUX study). Ann Oncol. 18:510–517. 2007.
View Article : Google Scholar
|
|
19
|
Lordick F, Kang YK, Chung HC, et al
Arbeitsgemeinschaft Internistische Onkologie and EXPAND
Investigators: Capecitabine and cisplatin with or without cetuximab
for patients with previously untreated advanced gastric cancer
(EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol.
14:490–499. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Waddel T, Chau I, Cunningham D, et al:
Epirubicin, oxaliplatin, and capecitabine with or without
panitumumab for patients with previously untreated advanced
oesophagogastric cancer (REAL3): a randomised, open-label phase 3
trial. Lancet Oncol. 14:481–489. 2013. View Article : Google Scholar
|
|
21
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bean J, Brennan C, Shih JY, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:20932–20937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chakravarti A, Loeffler JS and Dyson NJ:
Insulin-like growth factor receptor I mediates resistance to
antiepidermal growth factor receptor therapy in primary human
glioblastoma cells through continued activation of phosphoinositide
3-kinase signaling. Cancer Res. 62:200–207. 2002.PubMed/NCBI
|
|
24
|
Ouban A, Muraca P, Yeatman T and Coppola
D: Expression and distribution of insulin-like growth factor-1
receptor in human carcinomas. Hum Pathol. 34:803–808. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pavelić K, Kolak T, Kapitanović S, et al:
Gastric cancer: the role of insulin-like growth factor 2 (IGF 2)
and its receptors (IGF 1R and M6-P/IGF 2R). J Pathol. 201:430–438.
2003. View Article : Google Scholar
|
|
26
|
Shiraishi T, Mori M, Yamagata M, et al:
Expression of insulin-like growth factor 2 mRNA in human gastric
cancer. Int J Oncol. 13:519–523. 1998.PubMed/NCBI
|
|
27
|
Baserga R: The IGF-I receptor in cancer
research. Exp Cell Res. 253:1–6. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu H and Rohan T: Role of the insulin-like
growth factor family in cancer development and progression. J Natl
Cancer Inst. 92:1472–1489. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zuo Q, Shi M, Li L, et al: Development of
cetuximab-resistant human nasopharyngeal carcinoma cell lines and
mechanisms of drug resistance. Biomed Pharmacother. 64:550–558.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oligny-Longpré G, Corbani M, Zhou J, et
al: Engagement of β-arrestin by transactivated insulin-like growth
factor receptor is needed for V2 vasopressin receptor-stimulated
ERK1/2 activation. Proc Natl Acad Sci USA. 109:E1028–E1037. 2012.
View Article : Google Scholar
|
|
31
|
Hamzeh M and Robaire B: Androgens activate
mitogen-activated protein kinase via epidermal growth factor
receptor/insulin-like growth factor 1 receptor in the mouse PC-1
cell line. J Endocrinol. 209:55–64. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang S, Huang WC, Li P, et al: Combating
trastuzumab resistance by targeting SRC, a common node downstream
of multiple resistance pathways. Nat Med. 17:461–469. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ligęza J, Ligęza J and Klein A: Growth
factor/growth factor receptor loops in autocrine growth regulation
of human prostate cancer DU145 cells. Acta Biochim Pol. 58:391–396.
2011.
|
|
34
|
Mayer EL and Krop IE: Advances in
targeting SRC in the treatment of breast cancer and other solid
malignancies. Clin Cancer Res. 16:3526–3532. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peterson GL: A simplification of the
protein assay method of Lowry et al. which is more generally
applicable. Anal Biochem. 83:346–356. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lièvre A, Bachet JB, Le Corre D, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Di Fiore F, Blanchard F, Charbonnier F, et
al: Clinical relevance of KRAS mutation detection in metastatic
colorectal cancer treated by Cetuximab plus chemotherapy. Br J
Cancer. 96:1166–1169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Di Nicolantonio F, Martini M, Molinari F,
et al: Wild-type BRAF is required for response to panitumumab or
cetuximab in metastatic colorectal cancer. J Clin Oncol.
26:5705–5712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Brose MS, Volpe P, Feldman M, et al: BRAF
and RAS mutations in human lung cancer and melanoma. Cancer Res.
62:6997–7000. 2002.PubMed/NCBI
|
|
40
|
Heindl S, Eggenstein E, Keller S, et al:
Relevance of MET activation and genetic alterations of KRAS and
E-cadherin for cetuximab sensitivity of gastric cancer cell lines.
J Cancer Res Clin Oncol. 138:843–858. 2012. View Article : Google Scholar
|
|
41
|
Rebucci M, Peixoto P, Dewitte A, et al:
Mechanisms underlying resistance to cetuximab in the HNSCC cell
line: Role of AKT inhibition in bypassing this resistance. Int J
Oncol. 38:189–200. 2011.
|
|
42
|
Cordero JB, Stefanatos RK, Myant K, et al:
Non-autonomous crosstalk between the Jak/Stat and Egfr pathways
mediates Apc1-driven intestinal stem cell hyperplasia in the
Drosophila adult midgut. Development. 139:4524–4535. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cavallo RA, Cox RT, Moline MM, et al:
Drosophila Tcf and Groucho interact to repress Wingless signalling
activity. Nature. 395:604–608. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brantjes H, Roose J, van De Wetering M and
Clevers H: All Tcf HMG box transcription factors interact with
Groucho-related co-repressors. Nucleic Acids Res. 29:1410–1419.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hasson P and Paroush Z: Crosstalk between
the EGFR and other signalling pathways at the level of the global
transcriptional corepressor Groucho/TLE. Br J Cancer. 96(Suppl):
R21–R25. 2007.PubMed/NCBI
|
|
46
|
Xu L, Zhang Y, Liu J, et al:
TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in
lipid rafts antagonizes TRAIL-induced apoptosis in gastric cancer
cells. Eur J Cancer. 48:3288–3299. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Morgillo F, Woo JK, Kim ES, et al:
Heterodimerization of insulin-like growth factor receptor/epidermal
growth factor receptor and induction of survivin expression
counteract the antitumor action of erlotinib. Cancer Res.
66:10100–10111. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pollak M: Insulin-like growth factor
physiology and cancer risk. Eur J Cancer. 36:1224–1228. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cortés-Sempere M, de-Miguel MP, Pernía O,
et al: IGFBP-3 methylation-derived deficiency mediates the
resistance to cisplatin through the activation of the IGFIR/Akt
pathway in non-small cell lung cancer. Oncogene. 32:1274–1283.
2013. View Article : Google Scholar
|
|
50
|
Peterson JE, Kulik G, Jelinek T, et al:
Src phosphorylates the insulin-like growth factor type I receptor
on the autophosphorylation sites. Requirement for transformation by
src. J Biol Chem. 271:31562–31571. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Flossmann-Kast BB, Jehle PM, Hoeflich A,
et al: Src stimulates insulin-link growth factor I
(IGF-I)-dependent cell proliferation by increasing IGF-I receptor
number in human pancreatic carcinoma cells. Cancer Res.
58:3551–3554. 1998.PubMed/NCBI
|
|
52
|
Lieskovska J, Ling Y, Badley-Clarke J and
Clemmons DR: The role of Src kinase in insulin-like growth
factor-dependent mitogenic signaling in vascular smooth muscle
cells. J Biol Chem. 281:25041–25053. 2006. View Article : Google Scholar : PubMed/NCBI
|
